title: Lafutidine-based triple therapy for Helicobacter pylori eradication.
abstract: OBJECTIVE
  For treating Helicobacter pylori infection, it is still debatable whether proton pump inhibitor can be replaced by H2-receptor antagonist without compromising efficacy. Lafutidine is a newly synthesized H2-receptor antagonist and has been shown to exhibit antisecretory action. This meta-analysis investigated the efficacy of lafutidine-based triple therapy for Helicobacter pylori infection. METHODOGY: We searched PUBMED; EMBASE, the Cochrane Library and Chinese Biomedical Database databases to identify randomized controlled trials regarding lafutidine-based triple therapy of Helicobacter pylori eradication.
  
  
  RESULTS
  Thirteen potential studies were retrieved, of which 3 met our inclusion criteria. Overall we observed Helicobacter pylori eradication rates were similar in the lafutidine group and the lansoprazole group (OR, 1.03; 95% CI, 0.64-1.66). The OR for the active stage ulcer cure rate was 0.78 (95% CI, 0.35, 1.71) for lafutidine-based triple therapy compared with lansoprazole-based triple therapy. Likewise, we observed symptom response and adverse events were similar in both groups.
  
  
  CONCLUSIONS
  Lafutidine-based triple therapy was as safe and effective as triple therapy including lansoprazole for Helicobacter pylori infection, and could be considered as an additional treatment option. However, more rigorous research is required to accurately assess the role of lafutidine in eradicating Helicobacter pylori infection.
authors.affiliation: The First Hospital of Lanzhou University, Lanzhou, China.
authors.forename: Qian
authors.initials: Q
authors.lastname: Ren
authors.forename: Bin
authors.initials: B
authors.lastname: Ma
authors.forename: Kehu
authors.initials: K
authors.lastname: Yang
authors.forename: Xiang
authors.initials: X
authors.lastname: Yan
mesh_terms: D000081:Acetamides / Q000008:administration & dosage* / Q000009:adverse effects; D000897:Anti-Ulcer Agents / Q000008:administration & dosage*; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics; D065731:Cytochrome P-450 CYP2C19; D004359:Drug Therapy, Combination; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects*; D006635:Histamine H2 Antagonists / Q000008:administration & dosage*; D006801:Humans; D010880:Piperidines / Q000008:administration & dosage* / Q000009:adverse effects; D011725:Pyridines / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D000081:Acetamides; D000897:Anti-Ulcer Agents; D006635:Histamine H2 Antagonists; D010880:Piperidines; D011725:Pyridines; C076948:lafutidine; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19